HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

atrial natriuretic factor precursor (79-98)

Also Known As:
kaliuretic peptide; pro-ANF (79-98); proatrial natriuretic factor (79-98)
Networked: 42 relevant articles (4 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Vesely, David L: 27 articles (04/2014 - 05/2002)
2. Vesely, D L: 11 articles (03/2010 - 03/2001)
3. Gower, William R: 9 articles (11/2007 - 01/2005)
4. Eichelbaum, Ehrentraud J: 8 articles (04/2009 - 09/2006)
5. Sun, Ying: 8 articles (04/2009 - 09/2006)
6. Vesely, Brian A: 8 articles (11/2007 - 01/2005)
7. Gower, W R: 7 articles (08/2008 - 11/2003)
8. Skelton, William P: 6 articles (06/2013 - 04/2009)
9. Alli, Abdel A: 6 articles (11/2007 - 01/2005)
10. Skelton, Michelle: 5 articles (06/2013 - 03/2012)

Related Diseases

1. Adenocarcinoma
2. Carcinoma (Carcinomatosis)
03/01/2010 - "Vessel dilator, atrial natriuretic peptide and kaliuretic peptide each eliminated one in six (17%) of the human squamous cell lung carcinomas. "
03/01/2010 - "The squamous cell lung carcinomas that were not eliminated, with the exception of the one LANP-treated tumour that decreased to only 2% of the volume of the untreated cancers, grew rapidly but their growth velocity compared to controls decreased by 76%, 40%, 38% and 25% in the vessel dilator, atrial natriuretic peptide, kaliuretic peptide and long-acting natriuretic peptide groups respectively (P < 0.05). "
01/01/2010 - "atrial natriuretic peptide, vessel dilator, kaliuretic peptide and long-acting natriuretic peptide (LANP) which decrease up to 97% of human pancreatic, breast, colon, prostate, kidney and ovarian carcinomas as well as small-cell and squamous cell lung cancer cells within 24 hours in cell culture. "
03/01/2013 - "Vessel dilator, kaliuretic peptide, ANP, and LANP maximally reduced the concentration of AKT by 47%, 45%, 52%, and 46% in human colorectal cancer cells (p<0.0001), by 60%, 61%, 64%, and 59% in human pancreatic carcinoma cells (p<0.0001), and by 31%, 32%, 31%, and 31% in renal adenocarcinoma cells (p<0.001). "
01/01/2011 - "The heart is a sophisticated endocrine gland synthesizing the atrial natriuretic peptide prohormone which contains four peptide hormones, i.e., atrial natriuretic peptide, vessel dilator, kaliuretic peptide and long-acting natriuretic peptide, which decrease up to 97% of human pancreatic, breast, colon, prostate, kidney and ovarian carcinomas as well as small-cell and squamous cell lung cancer cells in cell culture. "
3. Neoplasms (Cancer)
4. Lung Neoplasms (Lung Cancer)
01/01/2010 - "atrial natriuretic peptide, vessel dilator, kaliuretic peptide and long-acting natriuretic peptide (LANP) which decrease up to 97% of human pancreatic, breast, colon, prostate, kidney and ovarian carcinomas as well as small-cell and squamous cell lung cancer cells within 24 hours in cell culture. "
02/28/2006 - "vessel dilator, long acting natriuretic peptide, kaliuretic peptide, and atrial natriuretic peptide and their intracellular mediator cyclic GMP decreased the number of human squamous lung cancer cells 51, 22, 25, 21, and 30%, respectively. "
03/01/2006 - "5. In cancer, vessel dilator, LANP, kaliuretic peptide and ANP at 1 mmol/L, decrease up to 97% of human breast, pancreatic and prostate adenocarcinoma cells, as well as small cell and squamous cell lung cancer cells within 24 h. "
01/01/2011 - "The heart is a sophisticated endocrine gland synthesizing the atrial natriuretic peptide prohormone which contains four peptide hormones, i.e., atrial natriuretic peptide, vessel dilator, kaliuretic peptide and long-acting natriuretic peptide, which decrease up to 97% of human pancreatic, breast, colon, prostate, kidney and ovarian carcinomas as well as small-cell and squamous cell lung cancer cells in cell culture. "
01/01/2009 - "Four cardiovascular hormones, ie, vessel dilator, long-acting natriuretic peptide, kaliuretic peptide, and atrial natriuretic peptide each at 1 mmol/L, decrease up to 97% of human breast, ovarian, pancreatic, colon, kidney, and prostate adenocarcinoma cells, as well as small cell and squamous cell lung cancer cells within 24 hours. "
5. Body Weight (Weight, Body)
07/01/2001 - "Kaliuretic peptide (100 ng/kg body weight/min) given intravenously for 60 minutes to subjects with New York Heart Association class III CHF increased urine flow fourfold (p <0.001), which was maximal 212 hours after its infusion was stopped. "
03/01/2001 - "Long-acting natriuretic peptide (LANP), vessel dilator, and kaliuretic peptide (100 ng/kg body weight/min) given intravenously for 60 minutes to NYHA Class III CHF patients (n = 24) increased the albumin excretion rate 2- to 7-fold (P <.001) and total protein excretion rate 2- to 5-fold (P <.001). "
10/01/2004 - "When these peptide hormones (each at 1.4 microg min(-1) kg(-1) body weight) were infused for 4 weeks, vessel dilator, long-acting natriuretic peptide and kaliuretic peptide decreased tumour volume after 1 week by 49%, 28%, and 11%, respectively, with a one- and 20-fold increase in the tumour volume in ANP- and placebo-treated mice. "
01/01/1996 - "Infusion of 100 ng/kg body weight/minute for 60 minutes of the respective atrial peptides resulted in a 4-fold (P < 0.001) increase in the circulating concentration of adrenomedullin secondary to the ANF infusion but no increase in adrenomedullin with the long acting natriuretic peptide, vessel dilator, or kaliuretic peptide infusions. "
05/01/2002 - "In 30 individuals with class III congestive heart failure (CHF), negative feedback of 4 cardiac peptide hormones, ie, long-acting natriuretic peptide (LANP), vessel dilator, kaliuretic peptide, and atrial natriuretic factor (ANF) from the same 126-amino acid (aa) prohormone were studied with the infusion of 100 ng/kg body weight (BW) for 60 minutes of each of the 4 cardiac hormones and a saline control (n = 6 for each). "

Related Drugs and Biologics

1. atrial natriuretic factor prohormone (31-67)
2. human atrial natriuretic factor prohormone (1-30)
3. Atrial Natriuretic Factor (ANF)
4. Hormones
5. atrial natriuretic factor prohormone (95-126) (Ularitide)
6. Cyclic GMP
7. Peptide Hormones (Polypeptide Hormones)
8. DNA (Deoxyribonucleic Acid)
9. Brain Natriuretic Peptide (Natrecor)
10. Phosphotransferases (Kinase)